Related Experiment Video
Updated: May 15, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Comprehensive Genomic Profiling of Rare Lung Tumors: Adenosquamous Carcinoma and Pulmonary Carcinosarcoma
Tianhao Zhou1, Olivia C Terry1, Katherine G Minton1
1Department of Internal Medicine, Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana.
Abstract:
In 2025, lung cancer remains the leading cause of cancer-related mortality in both men and women. Although the advent of immunotherapy and targeted therapies has revolutionized the treatment of NSCLC, treatments for rare histologic types such as adenosquamous carcinoma and pulmonary carcinosarcoma remain limited owing to insufficient data on molecular profiling. As such, knowledge of the molecular characteristics of rare tumors to inform treatment modalities for targeted approaches is desperately needed. In collaboration with Caris Life Sciences, we present new molecular profiling data including genomic, transcriptomic, and the current landscape of surrogate biomarkers to predict response to immunotherapy for ASC and PC to aid in expanding knowledge of these rare tumors and expediting novel therapies.
Insights
Molecular profiling of rare lung cancers like adenosquamous carcinoma (ASC) and pulmonary carcinosarcoma (PC) is crucial. New data on genomic, transcriptomic, and biomarker landscapes can guide targeted therapies and immunotherapy for these challenging diseases.
Area of Science:
- Oncology
- Genomics
- Translational Research
Background:
- Lung cancer is a leading cause of cancer mortality globally.
- Standard treatments are effective for non-small cell lung cancer (NSCLC), but rare histologic subtypes lack sufficient molecular data.
- Adenosquamous carcinoma (ASC) and pulmonary carcinosarcoma (PC) represent rare, challenging-to-treat lung cancers.
Purpose of the Study:
- To present novel molecular profiling data for rare lung cancer subtypes (ASC and PC).
- To identify genomic, transcriptomic, and surrogate biomarker profiles.
- To inform the development of targeted therapies and predict immunotherapy response.
Main Methods:
- Collaboration with Caris Life Sciences for molecular profiling.
- Analysis of genomic and transcriptomic data.
- Evaluation of surrogate biomarkers for immunotherapy response prediction.
Main Results:
- Presentation of new molecular profiling data for ASC and PC.
- Characterization of the current landscape of predictive biomarkers.
- Data aims to expand knowledge and expedite novel therapeutic strategies.
Conclusions:
- Comprehensive molecular profiling is essential for rare lung cancers.
- Understanding molecular characteristics can guide personalized treatment approaches.
- This research facilitates the advancement of novel therapies for ASC and PC.
More Related Videos
11:20Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
Published on: March 21, 2018
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:21Cancer Survival Analysis